Evidence map›Paper›PMID 26358171›Full record

ArticleThe Journal of clinical endocrinology and metabolism2015

Role of Endothelin-1 in a Syndrome of Myelofibrosis and Osteosclerosis.

Ralph Yachoui, Jasmin Kristianto, Kajal Sitwala, Robert D Blank

Open access · bronzeAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Endothelin Signaling in Bone.Endocrinology and metabolism clinics of North America · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Ralph YachouiDivision of Rheumatology, Department of Medicine (R.Y.), Department of Pathology (K.S.), Marshfield Clinic, Marshfield, Wisconsin 54449; Endocrine and Reproductive Physiology Program (J.K., R.D.B.), University of Wisconsin, Madison, Wisconsin 53706; Division of Endocrinology, Metabolism, and Clinical Nutrition, Department of Medicine (R.D.B.), Medical College of Wisconsin, Milwaukee, Wisconsin 53226; and Division of Endocrinology, Medical Service (R.D.B.), Clement J. Zablocki Veterans Administration Medical Center, Milwaukee, Wisconsin 53295.
Jasmin KristiantoDivision of Rheumatology, Department of Medicine (R.Y.), Department of Pathology (K.S.), Marshfield Clinic, Marshfield, Wisconsin 54449; Endocrine and Reproductive Physiology Program (J.K., R.D.B.), University of Wisconsin, Madison, Wisconsin 53706; Division of Endocrinology, Metabolism, and Clinical Nutrition, Department of Medicine (R.D.B.), Medical College of Wisconsin, Milwaukee, Wisconsin 53226; and Division of Endocrinology, Medical Service (R.D.B.), Clement J. Zablocki Veterans Administration Medical Center, Milwaukee, Wisconsin 53295.
Kajal SitwalaDivision of Rheumatology, Department of Medicine (R.Y.), Department of Pathology (K.S.), Marshfield Clinic, Marshfield, Wisconsin 54449; Endocrine and Reproductive Physiology Program (J.K., R.D.B.), University of Wisconsin, Madison, Wisconsin 53706; Division of Endocrinology, Metabolism, and Clinical Nutrition, Department of Medicine (R.D.B.), Medical College of Wisconsin, Milwaukee, Wisconsin 53226; and Division of Endocrinology, Medical Service (R.D.B.), Clement J. Zablocki Veterans Administration Medical Center, Milwaukee, Wisconsin 53295.
Robert D BlankDivision of Rheumatology, Department of Medicine (R.Y.), Department of Pathology (K.S.), Marshfield Clinic, Marshfield, Wisconsin 54449; Endocrine and Reproductive Physiology Program (J.K., R.D.B.), University of Wisconsin, Madison, Wisconsin 53706; Division of Endocrinology, Metabolism, and Clinical Nutrition, Department of Medicine (R.D.B.), Medical College of Wisconsin, Milwaukee, Wisconsin 53226; and Division of Endocrinology, Medical Service (R.D.B.), Clement J. Zablocki Veterans Administration Medical Center, Milwaukee, Wisconsin 53295.
Marshfield Clinic · USMarshfield Clinic · USMilwaukee VA Medical Center · USUniversity of Wisconsin–Madison · US

Funding

Congenic Mouse Strains Harboring Bone Strength Quantitative Trait LociR01AR054753 · NIAMS · UNIVERSITY OF WISCONSIN-MADISON · PI BLANK, ROBERT DANIEL · 2009 to 2013
$1.6M
Interaction of Mechanical Loading and Teriparatide on Bone Mass and PerformanceI21RX001440 · VA · CLEMENT J. ZABLOCKI VA MEDICAL CENTER · PI BLANK, ROBERT DANIEL · 2015 to 2019
–
NIAMS NIH HHS R01 AR054753RRD VA I21 RX001440
6 · The paper itself

Abstract

contextPrimary myelofibrosis is one of the chronic myeloproliferative disorders characterized by bone marrow fibrosis associated with extramedullary hematopoiesis and osteosclerosis. Endothelin-1 (ET1) is a potent vasoconstrictor that is also a key mediator of osteoblastic bone metastases by stimulating osteoblast proliferation and new bone formation. CASE DESCRIPTION: We report laboratory, radiographic, bone densitometry, and bone histology data of a patient presenting with newly diagnosed, biopsy-proven myelofibrosis and osteosclerosis. We were able to demonstrate abundant ET1 signaling in the bones of our patient.

conclusionsWe believe that ET1 is responsible for the osteosclerosis that develops with advanced myelofibrosis and suggest that ET1 signaling may play a role in other osteosclerotic settings as well.

Indexed as

Bone and BonesBone MarrowEndothelin-1FemaleHumansMiddle AgedOsteosclerosisPrimary MyelofibrosisSignal TransductionSyndromeEndothelin-1

Identifiers

PMID26358171
PMCPMC5399504
OpenAlexW2112967762

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.